Ensign Peak Advisors
MIRM icon

Ensign Peak Advisors’s Mirum Pharmaceuticals MIRM Stock Holding History

Ensign Peak Advisors’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.6M Sell
175,598
-26,875
-13% -$2.7M 0.03% 322
2026
Q1 		$18.7M Buy
202,473
+68,500
+51% +$6.44M 0.03% 314
2025
Q4 		$10.6M Hold
133,973
– – 0.02% 394
2025
Q3 		$9.82M Hold
133,973
– – 0.02% 461
2025
Q2 		$6.82M Hold
133,973
– – 0.01% 570
2025
Q1 		$6.04M Sell
133,973
-84,615
-39% -$3.99M 0.01% 589
2024
Q4 		$9.04M Sell
218,588
-1,806
-0.8% -$75.3K 0.02% 506
2024
Q3 		$8.6M Sell
220,394
-2,220
-1% -$88.6K 0.02% 502
2024
Q2 		$7.61M Hold
222,614
– – 0.01% 520
2024
Q1 		$5.59M Hold
222,614
– – 0.01% 606
2023
Q4 		$6.57M Hold
222,614
– – 0.01% 557
2023
Q3 		$7.03M Sell
222,614
-3,086
-1% -$84.5K 0.02% 485
2023
Q2 		$5.84M Hold
225,700
– – 0.01% 544
2023
Q1 		$5.42M Hold
225,700
– – 0.01% 541
2022
Q4 		$4.4M Sell
225,700
-5,250
-2% -$104K 0.01% 592
2022
Q3 		$4.85M Buy
230,950
+73,903
+47% +$1.78M 0.01% 528
2022
Q2 		$3.06M Buy
157,047
+30,654
+24% +$723K 0.01% 657
2022
Q1 		$2.78M Hold
126,393
– – 0.01% 759
2021
Q4 		$2.02M Hold
126,393
– – ﹤0.01% 950
2021
Q3 		$2.52M Hold
126,393
– – 0.01% 980
2021
Q2 		$2.19M Hold
126,393
– – ﹤0.01% 1085
2021
Q1 		$2.5M Hold
126,393
– – 0.01% 991
2020
Q4 		$2.21M Buy
126,393
+100,000
+379% +$1.97M 0.01% 1004
2020
Q3 		$509K Buy
26,393
+24,540
+1,324% +$527K ﹤0.01% 1527
2020
Q2 		$36K Hold
1,853
– – ﹤0.01% 1666
2020
Q1 		$26K Sell
1,853
-2,853
-61% -$46.8K ﹤0.01% 1617
2019
Q4 		$116K Buy
+4,706
New +$50.2K ﹤0.01% 1644

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ensign Peak Advisors's MIRM Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Mirum Pharmaceuticals (MIRM) stake by 13% in Q2 2026, selling an estimated $2.7M and leaving 175,598 shares worth $20.6M. The position accounts for 0.03% of the portfolio, ranked #322.

Ensign Peak Advisors first reported a position in MIRM in Q4 2019 and has held it in 27 quarters since. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Ensign Peak Advisors held 175,598 shares of Mirum Pharmaceuticals worth $20.6M as of Q2 2026.
  • Ensign Peak Advisors sold 26,875 Mirum Pharmaceuticals shares in Q2 2026, an estimated $2.7M.
  • Mirum Pharmaceuticals made up 0.03% of Ensign Peak Advisors's portfolio in Q2 2026, its #322 holding.
  • Ensign Peak Advisors first reported a position in Mirum Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.